Introduction: Prospective evidence on the relation between time in bed and renal dysfunction remains limited. We aimed to investigate the association of time spent in bed attempting to sleep (TSBS) with renal function decline in a middle-aged and elderly Chinese population.Methods: About 16,733 eligible participants with a mean age of 62.3 years at baseline were included. Rapid renal function decline was defined as (baseline eGFR???revisit eGFR)/years of follow-up ≥5?mL/min per 1.73 m2/year. A total of 1738 study participants experienced rapid renal function decline after a median 4.6-year follow-up. Logistic regression models were used for multivariate analyses.Results: The adjusted odds ratio (OR) of rapid renal function decline was 1.18 (95% CI: 1.02, 1.37) for TSBS ≥9?h/night compared with TSBS 7 to <8?h/night. This association remained significant (OR?=?1.19, 95% CI: 1.03, 1.38) after further adjustment for sleep quality, midday napping and usage of sleeping pills. Particularly, the association appeared to be prominent in individuals with diabetes.Conclusions: Longer TSBS (≥9?h) was independently associated with an increased risk of rapid renal function decline. Our findings emphasized the importance to have optimal TSBS.
Key messages
Our study firstly investigated the association between time spent in bed attempting to sleep (TSBS) and renal dysfunction in Chinese adults.
Compared with individuals TSBS 7 to <8?h, individuals with TSBS ≥9?h had 19% increased risk for rapid renal function decline after adjustment for multivariate confounders.
The association appeared to be prominent in individuals with diabetes.
A new colorimetric and fluorescence molecular chemosensor based on triazole hydrazone can be used as a multi-probe for selective detection of Al3+, Zn2+, and Cu2+ by monitoring changes in the absorption and fluorescence spectral patterns. Results show that Al3+ and Zn2+ ions can induce remarkable fluorescence enhancement at pH 6.0 and pH 10.0, respectively, while the addition of Cu2+ ions leads to a significant UV-visible absorption enhancement in the visible range at pH 6.0. In addition, the resultant Al3+ complex could act as an ‘on–off’ fluorescence sensor for F−. The fluorescence sensor was also used to monitor intracellular Al3+, Zn2+, and F− in Hela cells.A fluorescent probe for Al3+ and Zn2+ was synthesised, and the resultant Al3+-complex was used for the detection of F−.相似文献
Tolerance induced by morphine and other opiates remains a major unresolved problem in the clinical management of pain. There is now good evidence for the importance of MAPKs in morphine-induced antinociceptive tolerance. A member of the MAPK kinase kinase family, TGF-β activated kinase 1 (TAK1) is the common upstream kinase of MAPKs. Here, we have assessed the involvement of TAK1 in the development of tolerance to morphine-induced analgesia.
Experimental Approach
The effects of an antagonist of TAK1 on morphine tolerance were investigated in vivo using the Randall–Selitto test, and the mechanism was investigated using Western blot and immunohistochemistry. The expression of TAK1 after chronic morphine exposure was also evaluated in vitro by immunohistochemistry.
Key Results
Chronic intrathecal morphine exposure up-regulated protein levels and phosphorylation of spinal TAK1. TAK1 immunoreactivity was co-localized with the neuronal marker NeuN. Intrathecal administration of 5Z-7-oxozeaenol (OZ), a selective TAK1 inhibitor, attenuated the loss of morphine analgesic potency and morphine-induced TAK1 up-regulation. Furthermore, OZ decreased the up-regulated expression of spinal p38 and JNK after repeated morphine exposure. In vitro studies demonstrated that sustained morphine treatment induced TAK1 up-regulation, which was reversed by co-administration of OZ. A bolus injection of OZ showed some reversal of established morphine antinociceptive tolerance.
Conclusions and Implications
TAK1 played a pivotal role in the development of morphine-induced antinociceptive tolerance. Modulation of TAK1 activation by the selective inhibitor OZ in the lumbar spinal cord may prove to be an attractive adjuvant therapy to attenuate such tolerance. 相似文献